• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Immune combination possibilities in the first-line treatment of metastatic renal cell cancer
Magy Onkol. 2023 Apr 22;67(1):53-58. Epub 2023 Feb 26.ABSTRACTFirst-line treatment of metastatic renal cancer can be divided into three main phases. The cytokine era was replaced by targeted therapies in 2006 with the introduction of tyrosine kinase inhibitors. Until 2018, the standard first-line therapy was the use of sunitinib or pazopanib. Over the past decade, numerous attempts have been made to combine these drugs, which are already approved or in development, but these attempts have not been successful, primarily because of intolerable toxicity. In 2018, we reached a new stage in the treatment of metastatic renal tum...
Source: Magyar Onkologia - April 22, 2023 Category: Cancer & Oncology Authors: Zs ófia Küronya Krisztina Bir ó Lajos G éczi Anik ó Maráz Source Type: research

Stereotactic radiotherapy with CyberKnife and linear accelerator in the management of malignant melanoma
Magy Onkol. 2022 Jun 20;66(2):127-133. Epub 2022 May 28.ABSTRACTStereotactic radiotherapy gains more and more importance in the management of malignant melanoma, owing to technical developments of recent years. This approach might be applied with success in solitary or oligometastatic cases, since the deliverable biological dose is far higher than that of conventional radiotherapy. Beyond chemotherapy of decreasing importance, there is a widening range of new targeted and immunotherapy agents, leading to longer survival times even in disseminated stages. This latter underlines that it is worth to treat metastatic lesions l...
Source: Magyar Onkologia - June 20, 2022 Category: Cancer & Oncology Authors: Levente Zsolt J ánváry Mih ály Kispál Source Type: research

mmunotherapy of cutaneous melanoma - update 2022
Magy Onkol. 2022 Jun 20;66(2):119-124. Epub 2022 Jun 6.ABSTRACTMelanoma treatment has been revolutionized during the last decade. Currently first line therapeutic options for advanced melanoma include immunotherapy with anti-PD-1 antibodies (combination of PD-1 and CTLA-4 blockers should be an option in a selected group of patients) or targeted therapy with BRAF and MEK inhibitors in BRAF V600 mutated tumors. This review aims to summarize long-term survival data of immunotherapy in cutaneous melanoma and to show possible directions of development in combined oncological modalities.PMID:35724388
Source: Magyar Onkologia - June 20, 2022 Category: Cancer & Oncology Authors: Judit Ol áh Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20